MG
SWTX

Michael Gelband’s SpringWorks Therapeutics SWTX Stock Holding History

Michael Gelband’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,785
Closed -$791K – 1956
2025
Q1 		$785K Buy
+17,785
New +$819K 0.01% 985
2024
Q4 		– Sell
-114,300
Closed -$3.66M – 2039
2024
Q3 		$3.66M Sell
114,300
-28,055
-20% -$1.05M 0.02% 529
2024
Q2 		$5.36M Buy
142,355
+108,884
+325% +$4.58M 0.04% 383
2024
Q1 		$1.65M Buy
+33,471
New +$1.55M 0.01% 780
2023
Q4 		– Sell
-27,022
Closed -$625K – 2027
2023
Q3 		$625K Buy
+27,022
New +$739K 0.01% 1158
2022
Q4 		– Sell
-84,573
Closed -$2.41M – 2114
2022
Q3 		$2.41M Buy
84,573
+57,652
+214% +$1.65M 0.03% 707
2022
Q2 		$663K Buy
+26,921
New +$985K 0.01% 1255
2021
Q1 		– Sell
-3,634
Closed -$264K – 2587
2020
Q4 		$264K Buy
+3,634
New +$234K ﹤0.01% 1601
2020
Q3 		– Sell
-8,267
Closed -$347K – 2216
2020
Q2 		$347K Sell
8,267
-22,729
-73% -$809K 0.01% 1243
2020
Q1 		$837K Buy
+30,996
New +$1.01M 0.05% 341

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Michael Gelband's SWTX Position: Q2 2025 in Review

Michael Gelband sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 17,785 shares — an estimated $791K sold.

Michael Gelband first reported a position in SWTX in Q1 2020 and held it in 10 quarters. The position peaked at $5.36M in Q2 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Michael Gelband reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Michael Gelband sold 17,785 SpringWorks Therapeutics shares in Q2 2025, an estimated $791K.
  • Michael Gelband first reported a position in SpringWorks Therapeutics in Q1 2020 and held it in 10 quarters.
  • Michael Gelband's SpringWorks Therapeutics position peaked at $5.36M in Q2 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.